Why the study?
Does the ACS:180 Cardiac Troponin I assay perform as efficiently as other cardiac biomarkers in diagnosing acute myocardial infarction in patients with suspected acute coronary syndromes?
Does the ACS:180 Cardiac Troponin I assay perform as efficiently as other cardiac biomarkers in diagnosing acute myocardial infarction in patients with suspected acute coronary syndromes?
Answers are grounded in this paper and cite their sources.
The ACS:180 cTnI assay demonstrates equivalent diagnostic efficiency to CK-MB and cTnT for acute myocardial infarction and risk stratification in unstable angina.
All patients admitted to the coronary care unit with suspected acute coronary syndromes were evaluated by serial electrocardiography and blood draws on admission and at 4 and 12h from admission. Diagnosis was based on conventional WHO criteria. Samples were measured for creatine kinase (CK), cardiac troponin T (cTnT), myoglobin, CK isoenzyme MB (CK-MB) and cardiac troponin I (cTnI). A set of samples from individuals undergoing extreme endurance training was also examined. Analytical imprecision was consistent with published quality goals. Samples were stable for cTnI under a range of storage conditions, including multiple freeze thaw cycles. CK-MB, cTnI and cTnT were equally efficient for the diagnosis of acute myocardial infarction, irrespective of the final diagnostic criteria used. Both cTnI and cTnT were of equal efficiency in the identification of a high-risk subgroup of patients with unstable angina. Significant elevations of cTnI were not seen in an e ndurance-training group.
No takes yet. Share an insight, caveat, or question.
Collinson et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: